http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016050945-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_46583b49082bd012bce6401fb6a842c3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243 |
| filingDate | 2015-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e268638f08179be40b13b6369a222144 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b00423ca7ef5e9f7f961f02f55a17ea http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c1f39da8c7765877036bc175c53ce11 |
| publicationDate | 2016-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2016050945-A1 |
| titleOfInvention | Pharmaceutical combinations comprising estrogen receptor-beta agonists with platinum drugs or paclitaxel for treating ovarian cancer |
| abstract | The invention provides a treatment of ovarian cancer, particularly ovarian cancer that is resistant to platinum-containing anti-cancer drugs, using an estrogen receptor β subtype (ERβ) agonist, wherein the treatment comprises administering the ERβ agonist to the patient, and administering a platinum-containing anti-cancer drug to the patient, the administrations being simultaneous, sequential or separate. The invention also provides an ERβ agonist and a platinum- containing anti-cancer drug for use in the treatment of ovarian cancer in a patient, wherein the treatment comprises administering the ERβ agonist to the patient, and administering the platinum-containing anti-cancer drug to the patient, the administrations being simultaneous, sequential or separate; a kit comprising an ERβ agonist, a platinum-containing anti-cancer drug, and a further compound suitable for the treatment of ovarian cancer; and an ERβ agonist for use in the treatment of ovarian cancer in a patient, or an ERβ agonist and a taxane for use in the treatment of ovarian cancer in a patient, wherein the treatment comprises administering the ERβ agonist to the patient, and administering a taxane to the patient, the administrations being simultaneous, sequential or separate. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114249680-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114249680-A |
| priorityDate | 2014-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 227.